Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Control side effects of the psychedelic renaissance

  1. Christoph Bublitz

    1. University of Hamburg, Hamburg, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Nicolas Langlitz

    1. The New School, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Dimitris Repantis

    1. Charité University Hospital Berlin, Berlin, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Australia is the first nation to license the medical use of the psychedelic drugs MDMA for post-traumatic stress disorder and psilocybin for depression (Nature 619, 227–228; 2023). There is a danger that this approval could encourage unsupervised uptake worldwide.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 620, 277 (2023)

doi: https://doi.org/10.1038/d41586-023-02495-8

Competing Interests

Research of all three authors is financed by the German Federal Ministry of Education and Research (01GP2214). D.R. is a founding member and honorary board chair of MAPS Deutschland. The Charité has received research grants from COMPASS Pathways and MAPS Europe.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links